Home >
FEATURED COMMENTARY
04 Aug 2015 01:12 PM
Clinical investigation forms the backbone and the history of medical oncology. Cancer clinical trials provide the evidence we need to demonstrate safety and efficacy before Food and Drug...
24 Aug 2015 04:28 PM
The new Expert Office Hours program will pair Palliative Care in Oncology Symposium attendees with a senior researcher to provide essential guidance and foster collaboration.
21 Aug 2015 08:03 AM
My patient mix comes in waves—some months it is mostly women with breast cancer struggling with adjuvant endocrine therapy or men in the aftermath of...
16 Aug 2015 01:37 PM
Sometimes, it seems like the easiest way to raise some physician’s hackles is to bring up something that “administration” is doing. Maybe it’s a practice change felt to make things run more smoothly...
13 Aug 2015 11:25 AM
The good kind of problem is having too many choices; the bad kind of problem is having too few choices. Today, I am writing about the ultimate in the good kind of problems: Being an exceptional...
13 Aug 2015 11:00 AM
By Don S. Dizon, MD, FACP, and Elaine M. Doroff Significant psychological distress often accompanies the first diagnosis of cancer, but for most patients, I find the distress fades as the cancer gets...
05 Aug 2015 09:49 AM
It is difficult (but not impossible) to reflect on the fact that one of the key reasons I went into medical oncology was the...
04 Aug 2015 01:52 PM
I’m sure I am not alone in saying that I am almost obsessively conscious of time. Namely, that there never seems to be enough of it. As busy oncologists, we all have constant demands on our time,...

Latest Comments & Discussions


ASCO University
26 Aug 2015 10:11 AM
Thank you to Drs. Greco and Nardi leading the discussion of this case and also to all of those who contributed to the conversation! The...

F Anthony Greco, MD
26 Aug 2015 10:09 AM
Course Faculty Summary I would also like to thank everyone for participating in this discussion. Below are my thoughts based on the...

Valentina Nardi
26 Aug 2015 10:08 AM
Course Faculty Summary Thank you for everyone who participated in this discussion. My summary thoughts for each case are below: In...

F Anthony Greco, MD
25 Aug 2015 09:18 AM
Course Faculty Response Good question. Although there are no data for ALK inhibitors in the adjuvant setting, for ALK rearranged lung...

Rami Manochakian, MD
24 Aug 2015 09:43 PM
Thank you for these two interesting cases. I guess I am getting to review them fairly late but I certainly enjoyed the conversation and the...

Pages

Most Read

Read more to answer the following questions: 1) What tumor types should be considered in the differential diagnosis of a CK7+ CK20- CUP? 2)Could you have performed additional immunohistochemical stains to try to determine the site of origin? 3) Is EML4-ALK fusion unique to lung adenocarcinomas? 4) ...
Clinical investigation forms the backbone and the history of medical oncology. Cancer clinical trials provide the evidence we need to demonstrate safety and efficacy before Food and Drug Administration (FDA) approval and evidence for our clinical treatment guidelines. However, it seems to be more...
This year’s Community Research Forum Annual Meeting is right around the corner. As Chair of the CRF Council, I am very excited about the Meeting and would like to invite you to participate in this unique opportunity.
By Don S. Dizon, MD, FACP, and Elaine M. Doroff Significant psychological distress often accompanies the first diagnosis of cancer, but for most patients, I find the distress fades as the cancer gets treated and ultimately becomes a part of their past. Life resumes a new normalcy, interrupted only...
I’m sure I am not alone in saying that I am almost obsessively conscious of time. Namely, that there never seems to be enough of it. As busy oncologists, we all have constant demands on our time, from our leadership, colleagues, drug company reps, insurers, and our families, not to mention the time...

Tweets from ASCO

Tweets from Oncology Community